CelltrionHealthcare
MENU
Yuflyma®
-
- Product Name : Yuflyma®▼
- INN : Adalimumab
- Indications : Rheumatoid arthritis, Axial spondyloarthritis, Psoriasis, Psoriatic arthritis, Crohn’s disease, Hidradenitis suppurativa, Ulcerative colitis, Uveitis, Paediatric plaque psoriasis, paediatric Crohn’s disease, paediatric ulcerative colitis, paediatric uveit
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : Mechanism of Action : The target of adalimumab is a protein called tumour necrosis factor (TNFα), which is involved in the immune (defence) system and is present at increased levels in the inflammatory diseases listed above. By attaching to TNFα, Yuflyma decreases the process of inflammation in these diseases.
- ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to HPRA Pharmacovigilance via www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.
This product description is for medical and educational purposes only and not intended to promote the product for any promotional campaign. For more details, please consult a doctor, nurse, pharmacist or other healthcare professional.
-
- Product Name : Vegzelma®▼
- INN : Bevacizumab
- Indications : Metastatic carcinoma of the colon or rectum, Metastatic breast cancer, Non-small cell lung cancer, Advanced and/or metastatic renal cell cancer, Epithelial ovarian/fallopian tube and primary peritoneal cancer, Cervical cancer (*based on Vegzelma-SmPC)
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : Mechanism of Action : Bevacizumab binds selectively to a protein called human vascular endothelial growth factor (VEGF), which is found on the lining of blood and lymph vessels in the body.
- ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to HPRA Pharmacovigilance via www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.
This product description is for medical and educational purposes only and not intended to promote the product for any promotional campaign. For more details, please consult a doctor, nurse, pharmacist or other healthcare professional.
-
- Product Name : Remsima®
- INN : Infliximab
- Indications : Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), Psoriasis
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : Mechanism of Action : Remsima works by selectively attaching to TNF alpha and blocking its action. TNF alpha is involved in inflammatory processes of the body so blocking it can reduce the inflammation in your body.
This product description is for medical and educational purposes only and not intended to promote the product for any promotional campaign. For more details, please consult a doctor, nurse, pharmacist or other healthcare professional.
-
- Product Name : Remsima®SC
- INN : Infliximab
- Indications : Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : Remsima works by selectively attaching to TNF alpha and blocking its action. TNF alpha is involved in inflammatory processes of the body so blocking it can reduce the inflammation in your body.
This product description is for medical and educational purposes only and not intended to promote the product for any promotional campaign. For more details, please consult a doctor, nurse, pharmacist or other healthcare professional.
-
- Product Name : Truxima®▼
- INN : Rituximab
- Indications : RituximabNon-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), Rheumatoid Arthritis(RA), Granulomatosis with Polyangiitis(GPA), Microscopic Polyangiitis(MPA)
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : It sticks to the surface of a type of white blood cell called “B-Lymphocyte”. When rituximab sticks to the surface of this cell, the cell dies.
- ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to HPRA Pharmacovigilance via www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.
This product description is for medical and educational purposes only and not intended to promote the product for any promotional campaign. For more details, please consult a doctor, nurse, pharmacist or other healthcare professional.
-
- Product Name : Herzuma®▼
- INN : Trastuzumab
- Indications : HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), Metastatic Gastric Cancer(MGC)
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When Herzuma binds to HER2 it stops the growth of such cells and causes them to die.
- ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to HPRA Pharmacovigilance via www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.
▼This product description is for medical and educational purposes only and not intended to promote the product for any promotional campaign. For more details, please consult a doctor, nurse, pharmacist or other healthcare professional.
